Synapse - David Straus

Results (361)

Epoetin alfa treatment improves quality of life and increases hemoglobin levels during chemotherapy for lymphoma, chronic lymphocytic leukemia (CLL), and multiple myeloma (MM) patients with mild-to-moderate anemia

Meeting Abstract

Straus, D. J.; Turner, R. R.; Testa, M. A.; Hayes, J. F.; Sarokhan, B. J.
Blood (2002)

Fulltext@MSK | Save

H. pylori-independent MALT lymphoma of the stomach: Excellent outcome with radiation alone

Meeting Abstract

Yahalom, J.; Portlock, C. S.; Gonzales, M.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Zelenetz, A. D.
Blood (2002)

Fulltext@MSK | Save

Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma

Book Section

Straus, D. J.
In Oertel, S. H.; Reiss, H. (Eds.) Immunosurveillance, Immunodeficiencies and Lymphoproliferations: Lymphoproliferative Disorders in Congenital and Acquired Immunodeficiencies (2002)

Fulltext@MSK | Save

Epoetin alfa as a supportive measure in hematologic malignancies

Journal Article

Straus, D. J.
Seminars in Hematology (2002)

Fulltext@MSK | Save

Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation

Journal Article

Pan, D.; Moskowitz, C. H.; Zelenetz, A. D.; Straus, D.; Kewalaramani, T.; Noy, A.; Qin, J.; Teruya-Feldstein, J.; Portlock, C. S.
The Cancer Journal (2002)

Fulltext@MSK | Save

Impact of early response to sequential high-dose chemotherapy on outcome of patients with advanced myeloma and poor prognostic features

Journal Article

Niesvizky, R.; Siegel, D.; Glassman, J.; Straus, D.; Fine, J.; Lyons, L.; Michaeli, J.
Leukemia and Lymphoma (2002)

Fulltext@MSK | Save

Hodgkin's disease

Book Section

Yahalom, J.; Straus, D.
In Pazdur, R.; Coia, L. R.; Hoskins, W. J.; Wagman, L. D. (Eds.) Cancer Management: A Multidisciplinary Approach. 5th ed (2001)

Fulltext@MSK | Save

Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD plus radiation therapy for early stage non bulky Hodgkin's disease

Meeting Abstract

Straus, D. J.; Yahalom, J.; Zelenetz, A. D.; Qin, J.; Myers, J.; Moskowitz, C. H.; Noy, A.; Bertino, J. R.; Portlock, C. S.
Blood (2001)

Fulltext@MSK | Save

Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT)